Alvar Agustí participará como coordinador científico de la Reunión “CHIESI PatienTalks” que con el patrocinio de Chiesi, se llevará a cabo el miércoles 29 de noviembre de 2023 en la Real Academia de Medicina de Barcelona.
Our understanding of the pathogenesis of COPD has changed very significantly over the past few years.
A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as «Aging (Albany NY)» and «Aging-US» by Web of Science) Volume 15, Issue 14, entitled, «Human senescent fibroblasts trigger progressive lung fibrosis in mice.»
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer.
The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial.
Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide. While tobacco smoking is a key risk factor, COPD also occurs in never-smokers (NS).
El 21 de junio se celebrará en CaixaFòrum Barcelona las XXXV Jornadas Técnicas del Institut Guttmann. Este año las jornadas están dedicadas a la humanización en la asistencia, con el foco en la neurorrehabilitación
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
Los próximos 3, 4 y 5 de mayo tendrán lugar el VII Simposium Internacional de la EPOC y Tabaco y el XVII Simposium Internacional sobre prevención y tratamiento del tabaquismo.
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»
